Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 9/20 | 0.37 |
| ▸ | MMP1 | P03956 | 4/20 | 0.37 |
| ▸ | MMP3 | P08254 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847080 | 1.00 | POLB (0.43) | POLBCNR2MEN1KMT2ACA12 | |
| SCHEMBL15608798 | 1.00 | POLB (0.43) | POLBCNR2MEN1KMT2ACA12 | |
| SCHEMBL20212169 | 1.00 | POLB (0.43) | POLBCNR2MEN1KMT2ACA12 | |
| SCHEMBL18109669 | 1.00 | POLB (0.43) | POLBCNR2MEN1KMT2ACA12 | |
| SCHEMBL2846748 | 0.94 | POLB (0.39) | POLBCNR2MEN1KMT2ACA12 | |
| SCHEMBL4205630 | 0.90 | POLB (0.40) | POLBCNR2MEN1KMT2AMMP2 | |
| SCHEMBL4205633 | 0.90 | POLB (0.40) | POLBCNR2MEN1KMT2AMMP2 | |
| SCHEMBL8624830 | 0.88 | POLB (0.42) | POLBCNR2MEN1KMT2A | |
| SCHEMBL7376886 | 0.88 | POLB (0.42) | POLBCNR2MEN1KMT2A | |
| SCHEMBL7373925 | 0.88 | POLB (0.42) | POLBCNR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377100-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| CN-112174960-B | Toll-like receptor modulating 4, 6-diamino-pyrido [3,2-D ] pyrimidine compounds | 吉利德科学公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-110177780-B | Pyrimidine compounds containing acidic groups | 阿普罗斯治疗公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-29 | — | — | US | disclosed |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| EP-3548478-B1 | PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS | APROS THERAPEUTICS INC (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | Apros Therapeutics, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210228713-A1 | TLR7 PEPTIDE CONJUGATES | Apros Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| CN-112512590-A | TLR7 peptide conjugates | 阿普罗斯治疗公司 | 2021-03-16 | — | — | CN | disclosed |
| CN-112513031-A | Acid group containing pyrimidine compounds useful for the treatment of diseases associated with the modulation of TLR7 | 阿普罗斯治疗公司 | 2021-03-16 | — | — | CN | disclosed |
| US-9533978-B2 | Pyrimidine derivatives and their use in the treatment of cancer and further diseases | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2017-01-03 | — | — | US | disclosed |
| EP-3097102-A1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | Gilead Sciences, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2015-03-19 | — | — | US | disclosed |
| US-8765939-B2 | Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers | ASTRAZENECA AB (SE) | 2014-07-01 | — | — | US | disclosed |
| US-20130045955-A1 | NOVEL COMPOUNDS | BENNETT NICHOLAS J (GB) | 2013-02-21 | — | — | US | disclosed |
| EP-2222648-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS | ASTRAZENECA AB (SE) | 2013-01-09 | — | — | EP | disclosed |
| US-8268990-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-09-18 | — | — | US | disclosed |
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | ASTRAZENECA UK LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
| US-20090209524-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122867-A1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | TYMS, TYMP, DPYD | POLB 119/4885CNR2 1530/4885MEN1 2396/4885 |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | POLB 2230/4885CNR2 357/4885MEN1 4835/4885 |
| US-20210228713-A1 | TLR7 PEPTIDE CONJUGATES | TLR7, TLR9, TLR8 | POLB 1712/4885CNR2 3479/4885MEN1 3950/4885 |
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | TYMS, TYMP, DPYD | POLB 119/4885CNR2 1530/4885MEN1 2396/4885 |
| US-20090209524-A1 | Novel Compounds | ABCG2, CYP4B1, CYP3A4 | POLB 4672/4885CNR2 248/4885MEN1 595/4885 |
| US-20130045955-A1 | NOVEL COMPOUNDS | ABCG2, F12, CFTR | POLB 4515/4885CNR2 208/4885MEN1 805/4885 |
| US-12377100-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | POLB 2230/4885CNR2 357/4885MEN1 4835/4885 |
| US-11173157-B2 | Substituted pyrimidines containing acidic groups as TLR7 modulators | TLR7, TLR9, MAVS | POLB 652/4885CNR2 2438/4885MEN1 4690/4885 |
| US-20160289229-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | POLB 2230/4885CNR2 357/4885MEN1 4835/4885 |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | HAVCR2, ENTPD5, HMGB3 | POLB 222/4885CNR2 2295/4885MEN1 4628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.